Proteomic Analysis of Ovarian Cancer Fluids
Author Information
Author(s): Hoskins Ebony R., Hood Brian L., Sun Mai, Krivak Thomas C., Edwards Robert P., Conrads Thomas P.
Primary Institution: University of Pittsburgh School of Medicine
Hypothesis
Can tumor relevant proteins be identified from ovarian cancer proximal fluids and validated in blood serum?
Conclusion
The study found that peroxiredoxin 1 (PRDX1) is significantly elevated in the serum of ovarian cancer patients compared to those with benign conditions.
Supporting Evidence
- 569 proteins were identified in tissue interstitial fluid (TIF) and 171 in ascites from ovarian cancer patients.
- PRDX1 was found to be nearly 6-fold higher in the serum of ovarian cancer patients compared to benign controls.
- The study utilized a validated ELISA to measure PRDX1 levels in serum.
Takeaway
Researchers looked at fluids from ovarian cancer patients to find proteins that could help detect the disease early, and they found one protein that is much higher in cancer patients' blood.
Methodology
The study used liquid chromatography-tandem mass spectrometry to analyze paired tissue interstitial fluid and ascites from ovarian cancer patients.
Limitations
The study's validation sample cohort was limited, which may affect the conclusions about PRDX1 as a screening biomarker.
Participant Demographics
Patients were primarily Caucasian women with advanced epithelial ovarian cancer.
Statistical Information
P-Value
0.0188
Statistical Significance
p=0.0188
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website